Breakthru Medicine's PIPE Funds Mid-Stage Neurodegenerative Push

Breakthru Medicine has secured $60 million in a private investment in public equity (PIPE) financing to advance its pipeline of small molecules designed to correct protein misfolding in neurodegenerative diseases. The company is developing BTM-101, an oral agent targeting TDP-43 pathology for amyotrophic lateral sclerosis (ALS), currently in Phase 1b, and BTM-202, a compound for certain tauopathies preparing for Phase 2. The proceeds are earmarked specifically to complete the ongoing Phase 1b study of BTM-101 and to initiate a Phase 2 trial for BTM-202 in progressive supranuclear palsy (PSP) in the second half of 2026. While the investor syndicate was not disclosed, the PIPE's size suggests institutional backing for Breakthru's mechanistic approach in a high-risk, high-reward area. Neurodegenerative drug development has seen renewed deal flow, with protein homeostasis emerging as a key frontier beyond amyloid and tau immunotherapies.